Skip to main content
    C

    Candel Therapeutics Inc (CADL)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $5.81
    -0.39 (-6.29%)

    Market Cap: $486.37M

    Last updated: Nov 17, 2026 at 11:04 AM ET

    Candel Therapeutics Inc (CADL) Competitors

    Updated Nov 17, 2026. Similar companies are ranked by business profile, size, sector and industry; metrics come from company filings and market prices.

    The companies most similar to Candel Therapeutics are CytomX Therapeutics (CTMX), Century Therapeutics (IPSC) and Indaptus Therapeutics (INDP). By market cap, Candel Therapeutics ranks 5th of the 13 companies on this page; Kura Oncology (KURA) is the largest at $713.90M.

    Peer Comparison

    CADL's ROIC of -43.5% is below the peer median of -32.8%, and its revenue growth of 0.0% is in line with the median. Like the median peer, it pays no dividend.

    CompanyMarket capP/EP/SNet marginROICRev growthDiv yield
    Candel Therapeutics (CADL)$486.37MN/AN/A0.0%-43.5%0.0%0.00%
    CytomX Therapeutics Inc (CTMX)$444.73MN/A31.0x0.0%-32.8%-71.7%0.00%
    Century Therapeutics Inc (IPSC)$299.63MN/AN/A0.0%N/A-100.0%0.00%
    Indaptus Therapeutics Inc (INDP)$422.38MN/AN/A0.0%N/A0.0%0.00%
    Cullinan Oncology LLC (CGEM)$667.39MN/AN/A0.0%N/A0.0%0.00%
    Avalo Therapeutics Inc (AVTX)$448.71MN/AN/A0.0%N/A-69.3%0.00%
    Nuvectis Pharma Inc (NVCT)$696.03MN/AN/A0.0%N/A0.0%0.00%
    Tevogen Bio Holdings Inc. (TVGN)$406.59MN/AN/A0.0%2022.8%0.0%0.00%
    Contineum Therapeutics, Inc. Class A Common Stock (CTNM)$387.16MN/AN/A0.0%N/A0.0%0.00%
    Kyverna Therapeutics, Inc. Common Stock (KYTX)$319.27MN/AN/A0.0%-81.5%0.0%0.00%
    Neurogene Inc (NGNE)$495.37MN/AN/A0.0%-28.5%0.0%0.00%
    Kura Oncology Inc (KURA)$713.90MN/A8.0x0.0%-1125.3%10.1%0.00%
    Prelude Therapeutics Inc (PRLD)$275.32MN/A16.3x-269.7%N/A41.0%0.00%
    Peer median$433.55MN/A16.3x0.0%-32.8%0.0%0.00%
    Market data as of Nov 17, 2026. Net margin covers the trailing 12 months, Rev growth compares the latest quarter with a year earlier and Div yield is the forward yield. P/E uses earnings per share for the last 12 months as companies report it, often adjusted, so it can show beside a negative net margin, which uses net income. P/E and P/S show N/A when those earnings or sales are negative or missing, or the multiple is above 1,000x.

    Similar Companies

    These are the 12 companies most similar to Candel Therapeutics, ranked by how closely their business, size, sector and industry match. All 12 are in one industry, Biotechnology.

    CompanyAboutPeers
    CytomX Therapeutics Inc (CTMX)
    CytomX Therapeutics, Inc. is an oncology-focused biopharmaceutical company in the United States.
    CTMX competitors
    Century Therapeutics Inc (IPSC)
    Century Therapeutics Inc. (Ticker: IPSC) is a leading biotechnology company specializing in allogenic cell therapy...
    IPSC competitors
    Indaptus Therapeutics Inc (INDP)
    Indaptus Therapeutics Inc. is a pioneering biotechnology firm focused on advancing immunotherapies that aim to transform cancer treatment paradigms.
    INDP competitors
    Cullinan Oncology LLC (CGEM)
    Cullinan Management, Inc., a biopharmaceutical company, is focused on developing a line of targeted oncology and immuno-oncology therapies for cancer patients...
    CGEM competitors
    Avalo Therapeutics Inc (AVTX)
    Avalo Therapeutics Inc is a forward-thinking clinical-stage biotechnology company focused on developing transformative therapies for rare and underserved...
    AVTX competitors
    Nuvectis Pharma Inc (NVCT)
    Nuvectis Pharma, Inc., a biopharmaceutical company, is focused on the development of targeted small molecule therapies for the treatment of cancer.
    NVCT competitors
    Tevogen Bio Holdings Inc. (TVGN)
    Tevogen Bio Holdings Inc. is a clinical-stage biotechnology company that develops off-the-shelf precision T cell therapeutics in virology, oncology...
    TVGN competitors
    Contineum Therapeutics, Inc. Class A Common Stock (CTNM)
    Contineum Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on discovering and developing novel oral small molecule therapies...
    CTNM competitors
    Kyverna Therapeutics, Inc. Common Stock (KYTX)
    Kyverna Therapeutics, Inc. is an innovative biotechnology company focused on advancing immunotherapies for autoimmune diseases and other significant health...
    KYTX competitors
    Neurogene Inc (NGNE)
    Neurogene Inc. is an innovative biotechnology company at the forefront of developing advanced gene therapies for rare neurological disorders...
    NGNE competitors
    Kura Oncology Inc (KURA)
    Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops drugs for the treatment of cancer in the United States.
    KURA competitors
    Prelude Therapeutics Inc (PRLD)
    Prelude Therapeutics Incorporated, a precision clinical-stage oncology company, focuses on the discovery and development of small molecule therapies optimized...
    PRLD competitors

    Frequently Asked Questions About CADL

    Who are Candel Therapeutics' main competitors?

    The companies most similar to Candel Therapeutics include CytomX Therapeutics (CTMX), Century Therapeutics (IPSC), Indaptus Therapeutics (INDP), Cullinan Oncology LLC (CGEM) and Avalo Therapeutics (AVTX), listed from the closest match.

    Who is Candel Therapeutics' biggest competitor?

    Kura Oncology (KURA) is the largest of the similar companies at $713.90M; CytomX Therapeutics (CTMX) is the closest match by business profile, size, sector and industry.

    How does CADL stock compare with its competitors?

    CADL's net margin is 0.0% against a peer median of 0.0%.

    Which of Candel Therapeutics' competitors pays a higher dividend?

    Candel Therapeutics pays no dividend. None of the similar companies with available yields has a higher forward dividend yield.

    Is Candel Therapeutics bigger than its competitors?

    No. Candel Therapeutics is 5th by market cap among the 13 companies on this page; the largest is Kura Oncology (KURA) at $713.90M.